Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy.
Jerrold H Levy, Ian Welsby, Lawrence T Goodnough
Index: Transfusion 54(5) , 1389-405; quiz 1388, (2014)
Full Text: HTML
Abstract
Fibrinogen plays a critical role in achieving and maintaining hemostasis and is fundamental to effective clot formation. There is increasing awareness of the important role of fibrinogen as a key target for the treatment and prevention of acquired bleeding. Fibrinogen is the first coagulation factor to fall to critically low levels (<1.0 g/L) during major hemorrhage (normal plasma fibrinogen levels range from 2.0 to 4.5 g/L), and current guidelines recommend maintaining the plasma fibrinogen level above 1.5 g/L. Fibrinogen supplementation can be achieved using plasma or cryoprecipitate; however, there are a number of safety concerns associated with these allogeneic blood products and there is a lack of high-quality evidence to support their use. Additionally, there is sometimes a long delay associated with the preparation of frozen products for infusion. Fibrinogen concentrate provides a promising alternative to allogeneic blood products and has a number of advantages: it allows a standardized dose of fibrinogen to be rapidly administered in a small volume, has a very good safety profile, and is virally inactivated as standard. Administration of fibrinogen concentrate, often guided by point-of-care viscoelastic testing to allow individualized dosing, has been successfully used as hemostatic therapy in a range of clinical settings, including cardiovascular surgery, postpartum hemorrhage, and trauma. Results show that fibrinogen concentrate is associated with a reduction or even total avoidance of allogeneic blood product transfusion. Fibrinogen concentrate represents an important option for the treatment of coagulopathic bleeding; further studies are needed to determine precise dosing strategies and thresholds for fibrinogen supplementation. © 2013 American Association of Blood Banks.
Related Compounds
Related Articles:
2013-11-01
[Anesth. Analg. 117(5) , 1063-71, (2013)]
2014-07-01
[Exp. Neurol. 257 , 186-204, (2014)]
2014-10-01
[J. Biosci. Bioeng. 118(4) , 372-7, (2014)]
2015-01-01
[Immunology 144(1) , 91-106, (2015)]
Effects of fibrinogen concentration on fibrin glue and bone powder scaffolds in bone regeneration.
2014-10-01
[J. Biosci. Bioeng. 118(4) , 469-75, (2014)]